Safety And Efficacy Of A Combination Of Paromomycin And Miltefosine For Two Vs. Three Courses In Patients With Post-Kala-Azar Dermal Leishmaniasis: An Observational Pilot Study

PKDL is a dermal form of leishmaniasis caused by protozoal parasite Leishmania donovani. It is characterized by macular, popular and nodular lesions or a mixture of these1. It is mainly seen in Sudan and India, where it follows treatment of visceral leishmaniasis (VL) in 50% and 5-10% of cases respectively2. A phase III study on miltefosine-paromomycin combination for 10 days for treatment of Indian visceral leishmaniasis (n=157) revealed high cure rate (98.7%) with minimal toxicity, good compliance, lesser treatment duration and non-inferiority to standard amphotericin B3. We, therefore, aimed to assess the efficacy and safety of miltefosine plus paromomycin combination in thirty PKDL patients.This article is protected by copyright. All rights reserved.